Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash

Clin Oncol (R Coll Radiol). 2006 Oct;18(8):637-9. doi: 10.1016/j.clon.2006.07.002.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / secondary
  • Bronchial Neoplasms / drug therapy
  • Bronchial Neoplasms / pathology*
  • Drug Hypersensitivity
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Female
  • Gefitinib
  • Humans
  • Middle Aged
  • Quinazolines / adverse effects*
  • Quinazolines / therapeutic use
  • Skin Diseases, Vesiculobullous / chemically induced*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Gefitinib